International Clinical Trial: A randomized, double.bind,acive-controled, muicenter phas ll clinica trial evalating the eficacy and safety of therapeuic BCG for the prevenion of postoperalive recurence of non.muscle-invasive bladder cancer in people aged 18 years and older

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118454) titled 'A randomized, double.bind,acive-controled, muicenter phas ll clinica trial evalating the eficacy and safety of therapeuic BCG for the prevenion of postoperalive recurence of non.muscle-invasive bladder cancer in people aged 18 years and older' on Feb. 5.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: Patients 18 years of age and older with medium or high risk non-muscular invasive bladder cancer (NMIBC) after resection of a transurethral bladder tumor

Intervention: Trial group:Therapeutic BCG vaccine (Produced by Anhui Zhifei Long...